Skip to content

Study · Ex vivo tissue · 2007

3 results

The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4.

Kater A, Henke MO, Rubin BK

Annals of the New York Academy of Sciences11 May 2007Cited by 37 (Europe PMC)

PMID17496063 (opens in a new tab)DOI10.1196/annals.1415.006 (opens in a new tab)PepBankPUB-17496063
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In cystic fibrosis sputum, thymosin beta‑4 decreased cohesivity in a dose-dependent way.

    In plain wordsIn lab tests of cystic fibrosis sputum, thymosin beta‑4 made the sputum less cohesive as the dose rose.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseSputum cohesivity, dose-dependent
    Study

    humann: not reported in source

    cystic fibrosis sputum
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    Dose not stated · added to sputum · 30 minAs given in this study (human).

    Source sentences

    Summary
    There was a dose-dependent decrease in cohesivity with Tbeta4
    1 context sentence
    Summary · context
    Dose-dependent CF sputum rheology and polymer structure were measured before and after the addition of excipient, dornase alfa, Tbeta4, gelsolin, and Tbeta4 or gelsolin with dornase for 30 min.
  2. 02LabEx vivo tissueActivity measurement

    In cystic fibrosis sputum, thymosin beta‑4 at 30 microg/mL decreased cohesivity over time.

    In plain wordsIn lab tests of cystic fibrosis sputum, thymosin beta‑4 made the sputum less cohesive over time.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseSputum cohesivity, time-dependent
    Study

    humann: not reported in source

    cystic fibrosis sputum
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    30 microg/mL · added to sputum · 0 to 60 minAs given in this study (human).

    Source sentences

    Summary
    a time-dependent decrease in cohesivity at 30 microg/mL.
    2 context sentences
    Summary · context
    Sputum was also incubated with Tbeta4 30 microg/mL, gelsolin 10 microg/mL or excipient for 0, 5, 10, 15, 20, or 60 min.
    Summary · context
    Dose-dependent CF sputum rheology and polymer structure were measured before and after the addition of excipient, dornase alfa, Tbeta4, gelsolin, and Tbeta4 or gelsolin with dornase for 30 min.

Studies that did not test the peptide alone1

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 03LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueActivity measurement

    In cystic fibrosis sputum, dornase alfa combined with thymosin beta‑4 at 1.5 microg/mL decreased elasticity by 65%.

    In plain wordsIn lab tests of cystic fibrosis sputum, dornase alfa with thymosin beta‑4 lowered elasticity by 65%.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseSputum elasticity with dornase alfa plus thymosin beta-4
    Study

    humann: not reported in source

    cystic fibrosis sputum
    Outcome group
    Respiratory function · Respiratory

    Measurements

    Elasticity decrease
    65%
    dornase alfa plus Tbeta4 1.5 microg/mL

    Source sentences

    Summary
    With the combination of dornase alfa and Tbeta4 at 1.5 microg/mL, there was a 65% decrease in elasticity (P = 0.013).
    1 context sentence
    Summary · context
    Dose-dependent CF sputum rheology and polymer structure were measured before and after the addition of excipient, dornase alfa, Tbeta4, gelsolin, and Tbeta4 or gelsolin with dornase for 30 min.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.